Skip to main content

Table 1 Characteristics of the 2660 patients with invasive micropapillary breast cancer

From: Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database

Characteristic All patients [cases (%)]
Total 2660
Age
 ≤ 50 years 564 (21.2)
 51–64 years 1031 (38.8)
 ≥ 65 years 1065 (40.0)
Race
 White 2169 (81.5)
 African American 351 (13.2)
 Others 140 (5.3)
Sex
 Female 2607 (98.0)
 Male 53 (2.0)
Charlson–Deyo comorbidity score
 0 2210 (83.1)
 1 362 (13.6)
 ≥ 2 88 (3.3)
Clinical T stage
 T1 1655 (62.2)
 T2 738 (27.7)
 T3 184 (6.9)
 T4 83 (3.1)
Clinical N stage
 N0 1998 (75.1)
 N1 532 (20.0)
 N2 81 (3.0)
 N3 49 (1.8)
Surgery
 Lumpectomy 1281 (48.2)
 Mastectomy 1379 (51.8)
Lymph nodes involved
 0 1243 (46.7)
 1–3 689 (25.9)
 ≥ 4 501 (18.8)
 Unknown 227 (8.5)
Histologic gradea
 1 196 (7.4)
 2 1333 (50.1)
 3 971 (36.5)
 Not reported 160 (6.0)
ER status
 Positive 2327 (87.5)
 Negative 291 (10.9)
 Unknown 42 (1.6)
PR status
 Positive 2112 (79.4)
 Negative 498 (18.7)
 Unknown 50 (1.9)
HER2 status
 Positive 397 (14.9)
 Negative 1498 (56.3)
 Unknown 765 (28.8)
Tumor markers
 ER+ HER2− 1402 (52.7)
 ER+ HER2+ 297 (11.2)
 ER− HER2+ 99 (3.7)
 ER− HER2− 95 (3.6)
 Not reported 767 (28.8)
Radiotherapy
 Yes 1592 (59.8)
 No 1068 (40.2)
Chemotherapy
 Yes 1273 (47.9)
 No 1024 (38.5)
 Not reported 363 (13.6)
Hormonal therapy
 Yes 1979 (74.4)
 No 501 (18.8)
 Not reported 180 (6.8)
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
  2. aWell, moderately, and poorly differentiated/undifferentiated tumors were classified into histologic grades 1, 2, and 3, respectively